Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;37(10):1629-1631.
doi: 10.1097/QAD.0000000000003600.

HIV drug resistance monitoring in the era of dolutegravir and injectable long-acting cabotegravir in resource-limited settings

Tendai Washaya  1   2 , Justen Manasa  1   2 , Vinie Kouamou  1   2
Affiliations

HIV drug resistance monitoring in the era of dolutegravir and injectable long-acting cabotegravir in resource-limited settings

Tendai Washaya et al. AIDS. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations. https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-.... [Accessed 16 October 2022]
    1. World Health Organization. who-hiv-policy-adoption-and-implementation-status-in-countries.pdf. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-.... [Accessed 22 October 2022]
    1. Zimbabwe ∣ UNAIDS. https://www.unaids.org/en/regionscountries/countries/zimbabwe [Accessed 17 April 2023].
    1. Kouamou V, Mavetera J, Manasa J, Ndhlovu CE, Katzenstein D, McGregor AM. Pretreatment HIV drug resistance among adults initiating or re-initiating first-line antiretroviral therapy in Zimbabwe: fast-tracking the transition to dolutegravir-based first-line regimens? AIDS Res Hum Retroviruses 2021; 37:776–783. - PubMed
    1. Chimbetete C, Shamu T, Keiser O. Zimbabwe’s national third-line antiretroviral therapy program: cohort description and treatment outcomes. PLoS One 2020;15:e0228601. - PMC - PubMed

MeSH terms